Cancer Translational Research: Harnessing our understanding of apoptosis in the treatment of cancer

The Apoptosis

All cells are mortal. They are designed to die at some part. This mechanism allows our bodies to keep homeostasis. The existing cells die to allow the spreading of younger cells. When cells encounter toxic substances, they begin their suicide button to retain the toxin. The process of programmed cell death is named apoptosis. This is actually the consequence of studies in Cancer Translational Research.

This can be one treatment tactic researched in cancer translational research, a discipline pairing laboratory and clinical findings to offer solutions, including diagnostic treatment, effective and safe treatment and prevention strategy, for the public health threat – cancer. Each time a normal body cell continues splitting and propagate all around the body thereby leading to physiologic distress, they may be called cancer cells. The thought of apoptosis as being at treating cancer is founded on the supposition that cancer cells could be developed to die using the apoptotic pathway.

Apoptosis and chemotherapy

It had been found out that chemotherapeutic drugs work by either inducing apoptosis or causing direct problems for cells. Thus, it’s possible to debate that apoptosis like a therapy is similar in results because the current chemotherapy. What benefits than does the apoptosis cancer translational research supply?

Apoptotic research is not ineffective whatsoever. Inhibition of anti-apoptotic proteins, Bcl-2 family and IAPs was found to function in wiping out cancer cells in animal models. Chemical agents, though do not cause direct cell death, were found to bar an upstream pathway of apoptosis. These are Herceptin for cancer of the breast, Iressa for lung cancer, and Gleevec for CML. All these agents will be in the trial stage. An alternative treatment strategy for non-Hodgkin’s lymphoma is Rituximab, an antibody directed for the B cell antigen B220 from the cancer cells.

Proposed mechanism of action of Rituximab is the induction of apoptosis. A protein called p-53 is discovered to induce apoptosis. A chemical agent MDM2 was discovered to activate p-53 thereby arrests cell cycle and initiate cell death. Scientists are also investigating a therapy strategy combining chemotherapy and apoptosis. They reason that this plan has much more probably been cured. Another proposed strategy involving apoptosis is eliminating a nutrient way to obtain cancer cells by killing the veins supplying them. This strategy was discovered to work in animal models involving the protein tumor necrosis factor (TNF).

The apoptotic mechanism offers a profitable strategy in cancer translational research. Rapid advancement in the area of apoptosis as well as the novel agents is grounds for optimism.

Leave a Reply

Your email address will not be published. Required fields are marked *